Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 22Uveal Melanoma 2Skin Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 13Bevacizumab 9Interleukin-2 8aldesleukin 7Paclitaxel 7fludarabine phosphate 6fludarabine 6Radiotherapy 6Bortezomib 6Thalidomide 5Gemcitabine 5Filgrastim 5veliparib 4sargramostim 4Vincristine 4Trastuzumab 4Prednisone 4Leucovorin 4Doxorubicin 4Biopsy 4vandetanib 3tariquidar 3romidepsin 3pazopanib 3montanide ISA 51 3Topotecan 3Specimen Handling 3Sorafenib 3Sirolimus 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasms × incomplete Freund's adjuvant × Clear all
NCT00001827 2017-10-06

p53 Vaccine for Ovarian Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
21 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡